June 24, 2011
By Bruce S. Rubin, MD
Assistant Professor of Clinical Neurology, University of Miami Miller School of Medicine
Opposing Views
Scientific advancements in medicine are important achievements that improve quality of life for many people. One recent example is in the field of biotech medicines. But in the rush to make generic versions of these drugs, patient safety could be compromised. Read More
June 23, 2011
Less expensive, follow-on biologics are expected to be a boon to patients and Washington’s biotechnology industry. But as the FDA implements a new approval pathway for these complicated drugs, the medical community wants to ensure patient safety comes first.
June 23, 2011
The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on biosimilar medicines. Clusters are topic areas of mutual interest for the two agencies, which they have identified as benefiting from the regular exchange of information and collaborative meetings. Biosimilar medicines is the latest addition to the existing list of topics, which already includes medicines to treat cancer, orphan medicines, medicines for children and blood-based products. Read more.
June 21, 2011
November 18, 2011
Seattle, WA
Read More
June 21, 2011
September 20, 2011
Institute for Stem Cell & Regenerative Medicine
Seattle, WA
Read More
June 17, 2011
The Biotechnology Industry Organization (BIO) announced today its selection of Virginia State Senator Mark Herring (D) of Leesberg as Legislator of the Year for 2009-2010. Senator Herring received the award today in the Virginia pavilion at the 2010 BIO International Convention taking place this week in Chicago, IL.
Read More
